Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treatment of infections caused by Acinetobacter baumannii including carbapenem-resistant and multidrug-resistant (MDR) strains, and ETX0462 a novel, first-in-class, diazabicyclooctane with broad spectrum antimicrobial activity against MDR Gram-negative bacteria, including Pseudomonas aeruginosa.